Missouri Pharmacy Program – Preferred Drug List

Anticoagulant Agents – Oral and Subcutaneous

Effective 01/10/2013
Revised 01/10/2019

Preferred Agents
Available with Clinical Edits

- Eliquis®
- **Enoxaparin**
- Fragmin®
- Pradaxa®
- Warfarin
- Xarelto®

Non-Preferred Agents
Available with Clinical Edits

- Arixtra®
- Coumadin®
- Fondaparinux
- **Lovenox®**
- **Savaysa®**

Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 3 or more preferred agents
  - Documented trial period for preferred agents
  - Documented ADE/ADR to preferred agents
- Documented compliance on current therapy regimen

- **Appropriate Diagnosis – Factor Xa Inhibitors, Direct Thrombin Inhibitors, Warfarin**

FDA Approved Indications	***Apixaban***[3] *(Eliquis®)*	***Dabigatran*** *(Pradaxa®)*	***Edoxaban***[4] *(Savaysa®)*	***Fondaparinux*** *(Arixtra®)*	***Rivaroxaban***[3] *(Xarelto®)*	***Warfarin*** *(Coumadin®)*	**Betrixaban** *(Bevyxxa®)*[5]
Prevention of stroke and systemic embolism with nonvalvular atrial fibrillation	**X**[3]	**X**	**X**[4] **(see footnote)**		**X**[3]	**X**	
DVT prophylaxis after hip replacement	**X**[3]	**X**		**X**	**X**[3]	**X**	
DVT Prophylaxis after knee replacement	**X**[3]			**X**	**X**[3]	**X**	
Treatment of DVT and PE	**X**[3]	**X**[1] **(see footnote)**	**X**[1,4] **(see footnote)**	**X**	**X**[3]	**X**[1] **(see footnote)**	
Prevention of recurrent DVT and/or PE	**X**[3]	**X**		**X**	**X**[3]	**X**	
Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement						**X**[2]	
Reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events after MI						**X**	
VTE prophylaxis in adult patients hospitalized for acute medical illness who are at risk due to restricted mobility or other risk factors for VTE							**X**[5]

1 Requires initial 5-10 day therapy with a parenteral anticoagulant
2 Atrial fibrillation due to any etiology
3 Tablets may be crushed and taken by mouth or via nasogastric tube or gastric feeding tube
4 Edoxaban should not be used in patients with creatinine clearance >95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied. Creatinine clearance should be assessed before starting edoxaban for the treatment of non-valvular atrial fibrillation.
5 Safety and efficacy not established in patients with prosthetic heart valves

- **Appropriate Diagnosis – Low Molecular Weight Heparins (LMWH's)**

FDA-Approved Indications:

	Dalteparin (Fragmin®)	Enoxaparin (Lovenox®)
Prophylaxis of DVT which may lead to PE in abdominal surgery and at risk for thromboembolic complications	**X**	**X**
Prophylaxis of DVT which may lead to PE in hip replacement surgery	**X**	**X***
Prophylaxis of DVT which may lead to PE in knee replacement surgery		**X**
Prophylaxis of DVT which may lead to PE in severely restricted mobility during acute illness	**X**	**X**
Treatment of acute DVT with or without PE		**X****
Prophylaxis of ischemic complications in unstable angina and non-Q wave MI	**X*****	**X*****
Extended treatment of symptomatic VTE (proximal DVT and/or PE) in cancer patients to reduce recurrence of VTE	**X**	
Treatment of acute ST-segment elevation myocardial infarction [STEMI] managed medically or with subsequent percutaneous coronary intervention		**X*****

*During and following hospitalization

**Approved for *inpatient* treatment of acute DVT *with or without PE* when administered in conjunction with warfarin; approved for *outpatient* treatment of DVT *without PE* when administered in conjunction with warfarin

***In conjunction with ASPIRIN

Denial Criteria

- Lack of adequate trial on required preferred agents
- Drug Prior Authorization Hotline: (800) 392-8030